Macrogenics takes another shot at a novel immune checkpoint
Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
Zymeworks investors wake up to competition
With mounting competition in Her2-directed breast cancer treatment, Zymeworks’ latecomer struggles to show that it’s better.
Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Bergenbio dream lives on, despite Genmab's broken Axl
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
Five Prime looks to turn a corner
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
